News & Events about Recursion Pharmaceuticals A.
Recursion to Participate in Upcoming Investor Conferences Recursion to Participate in Upcoming Investor Conferences PR Newswire SALT LAKE CITY, Dec. 20, 2022 SALT LAKE CITY, Dec. 20, 2022 /PRNewswire/ --Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX Get Rating) insider Shafique Virani sold 10,000 shares of the businesss stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $13.36, for a total value of $133,600.00. Following the ...
Exscientia (NASDAQ:EXAI Get Rating) and Recursion Pharmaceuticals (NASDAQ:RXRX Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ...
Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference PR Newswire SALT...
Bank of America Corp DE grew its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX Get Rating) by 545.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 171,175 shares of the companys stock after acquiring...